Global sales for surgical heart valve management products are expected to stay relatively flat by 2023 while percutaneous balloon valvuloplasty (PBV) systems are expected to see double-digit growth, according to a new analysis from Informa's Meddevicetracker titled "Surgical Heart Valve Management Products."
Total worldwide heart valve management product sales are projected to decline at a compound annual growth rate (CAGR) of -0.2% to $2.0bn in 2023, based primarily on competition from minimally invasive transcatheter products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?